High Efficacy of Therapeutic Equine Hyperimmune Antibodies Against SARS-CoV-2 Variants of Concern

 

Gorde:
Xehetasun bibliografikoak
Egileak: Moreira Soto, Andrés, Gutiérrez, José María, Alape Girón, Alberto, Drexler, Jan Felix, Arguedas Gómez, Mauricio, Brenes Porras, Hebleen, Buján Boza, Willem Aart, Corrales Aguilar, Eugenia, Díaz Oreiro, Cecilia, Echeverri McCandless, Ann, Flores Díaz, Marietta, Macaya Hayes, Román, Kühne, Arne, Molina Mora, José Arturo, Mora Rodríguez, Javier Francisco, Sanabria Castro, Alfredo, Sánchez Brenes, Andrés, Sánchez Céspedes, Laura Vanessa, Segura Ruiz, Álvaro, Segura Agüero, Eduardo, Solano Centeno, Daniela, Soto Garita, Claudio, Stynoski, Jennifer Lynn, Vargas Arroyo, Mariángela, Villalta Arrieta, Mauren, Reusken, Chantal B. E. M., Drosten, Christian
Formatua: artículo original
Argitaratze data:2021
Deskribapena:SARS-CoV-2 variants of concern show reduced neutralization by vaccine-induced and therapeutic monoclonal antibodies; therefore, treatment alternatives are needed. We tested therapeutic equine polyclonal antibodies (pAbs) that are being assessed in clinical trials in Costa Rica against five globally circulating variants of concern: alpha, beta, epsilon, gamma and delta, using plaque reduction neutralization assays. We show that equine pAbs efficiently neutralize the variants of concern, with inhibitory concentrations in the range of 0.146–1.078µg/mL, which correspond to extremely low concentrations when compared to pAbs doses used in clinical trials. Equine pAbs are an effective, broad coverage, low-cost and a scalable COVID-19 treatment.
Herria:Kérwá
Erakundea:Universidad de Costa Rica
Repositorio:Kérwá
Hizkuntza:Inglés
OAI Identifier:oai:kerwa.ucr.ac.cr:10669/85930
Sarrera elektronikoa:https://www.frontiersin.org/articles/10.3389/fmed.2021.735853/full
https://hdl.handle.net/10669/85930
Gako-hitza:Equine antibodies
SARS-CoV-2
Therapy
Variant of concern
PRNT titers 50
Neutralization test
COVID-19
VIROLOGÍA

Antzeko izenburuak